Summary (10 sec read)
Experience in nuclear medicine is crucial for effective treatment. At our center, we provide Lutetium-177 PSMA therapy weekly to patients from around the world. Alpha therapy (Actinium-225 PSMA) and Terbium-161 therapy are also offered monthly, ensuring access to cutting-edge, precision-targeted treatments under the expertise of seasoned specialist
When a patient is diagnosed with advanced prostate cancer, the journey ahead is often uncertain. Conventional treatments—surgery, radiation, chemotherapy—may have already been exhausted, and the search for alternatives begins. In recent years, nuclear medicine has emerged as a promising option, offering targeted therapies that can slow the disease’s progression. Among these, Lutetium-177 PSMA therapy has gained attention, showing potential in patients for whom other treatments have failed.
At Fortis Memorial Research Institute (FMRI) in Gurugram, India, Dr. Ishita B. Sen has spent years working with nuclear medicine therapies, refining treatment protocols, and adapting them to the unique needs of each patient. Her expertise goes beyond a single molecule. While Lu-177 PSMA has helped many, it is not always the best or only option. Some patients respond better to Alpha-PSMA therapy, which uses Actinium-225—a more potent isotope that delivers radiation over a shorter range, reducing damage to surrounding healthy tissues. Others may benefit from Terbium-161, an emerging radionuclide that combines beta and Auger electron emissions, offering a different mechanism of targeting cancer cells.
Dr. Sen’s experience is not limited to prostate cancer. She has also worked extensively with Yttrium-90 (Y-90) radioembolization, a treatment for liver cancer that delivers radiation directly to liver tumors. The underlying principle in all these therapies is the same: precision. Unlike chemotherapy, which affects the entire body, nuclear medicine delivers radiation specifically to cancer cells, minimizing systemic side effects. But precision is not just about the molecule—it is also about how the therapy is administered. Dose calculations, timing, patient selection—all play a role in determining the outcome.
This is where experience matters. Nuclear medicine is evolving, with new isotopes and techniques emerging regularly. Having a clinician who understands these developments and can tailor treatment accordingly makes a significant difference. The question is not simply whether a therapy works, but whether it works for a particular patient, at a particular stage of their illness.
For those navigating treatment decisions, information can be just as important as the therapy itself. Until the end of March 2025, Dr. Sen is offering free second opinions, allowing patients and caregivers to discuss their cases and explore available options. It is an opportunity to gain clarity, to understand what nuclear medicine can and cannot do, and to make informed choices about the next steps.
For inquiries, patients can reach out via www.nuclearmedicinetherapy.in or email info@nuclearmedicinetherapy.in.
Cancer treatment is rarely straightforward. But having access to expertise, honest guidance, and a thoughtful approach can make the path ahead a little clearer.